is there currently a research gap in ctDNA as a predictor of surgical margins and recurrence in GI cancers. let me know if this is a good meta analysis focused topic.
Searching PubMed
ctDNA circulating tumor DNA surgical margins gastrointestinal cancer
Searching PubMed
ctDNA recurrence prediction GI cancer colorectal pancreatic resection
Searching PubMed
circulating tumor DNA meta-analysis gastrointestinal cancer prognosis
Searching the Web
ctDNA surgical margins recurrence GI cancers meta-analysis research gap 2024 2025
Reading Article
Reading Article
Reading Article
Searching PubMed
ctDNA postoperative minimal residual disease pancreatic hepatocellular cholangiocarcinoma recurrence
Searching PubMed
ctDNA R0 R1 resection margin status colorectal pancreatic cancer
Searching PubMed
circulating tumor DNA pancreatic cancer resection recurrence prognosis
Reading Article
Reading Article
Searching PubMed
ctDNA surgical resection margin recurrence prediction pan-GI cancer
I now have a solid picture of the literature. Let me compile the full analysis.
Is "ctDNA as a Predictor of Surgical Margins and Recurrence in GI Cancers" a Good Meta-Analysis Topic?
Short verdict: Yes - with an important refinement. The "surgical margins" angle is the true gap. Recurrence prediction by ctDNA already has several cancer-specific meta-analyses. But a pan-GI meta-analysis that directly addresses margin status (R0/R1/R2) as a ctDNA correlate AND recurrence, treating these as linked outcomes, has not been done.
1. What Literature Already Exists (The "Taken" Ground)
The following meta-analyses have been published, meaning these specific angles are already covered:
| Cancer Type | What's Already Meta-Analyzed | PMID |
|---|---|---|
| Gastric cancer | ctDNA positivity vs. recurrence/RFS/OS after surgery | 38050202 (2023) |
| Stage II colorectal | Post-op ctDNA as MRD/recurrence predictor | 40141130 (2025) |
| Locally advanced rectal | ctDNA for treatment stratification and prognosis | 37553845 (2023) |
| Esophageal cancer | ctDNA after neoadjuvant therapy + esophagectomy | 40793951 (2025), 38267901 (2024) |
| Metastatic CRC | ctDNA during systemic therapy, prognosis | 40743933 (2025) |
None of these cross GI cancer subtypes into a unified analysis, and none directly correlate ctDNA with pathological margin status (R0 vs R1/R2) as a primary outcome.
2. The Genuine Research Gaps
Gap A - The surgical margin angle (strongest gap):
A PubMed search for "ctDNA + surgical margins + GI cancer" returns zero results. There is no study - let alone a meta-analysis - that has systematically evaluated whether preoperative or intraoperative ctDNA levels predict margin clearance (R0 vs R1). Individual studies occasionally mention margin status as a covariate, but it has never been analyzed as a primary ctDNA endpoint. This is a clinically meaningful gap because surgeons need real-time biomarkers to guide re-resection decisions.
Gap B - Pan-GI unified analysis:
Existing meta-analyses are cancer-specific silos (gastric only, rectal only, esophageal only). A cross-GI meta-analysis comparing ctDNA predictive performance across colorectal, gastric, pancreatic, hepatobiliary, and esophageal cancers after curative-intent surgery would itself be novel. The 2026 Safiejko review (PMID 41899615) makes this exact point: "ctDNA is a clinically validated biomarker for MRD in CRC, whereas in other GI cancers, it remains a promising but methodologically heterogeneous tool."
Gap C - Pancreatic and hepatobiliary MRD:
For PDAC specifically, the most recent studies (Aaquist 2026, PMID 41421722; Ojha 2025, PMID 41294651) are still single-center observational studies and call for pooled data. No meta-analysis on ctDNA as a recurrence predictor in resected pancreatic cancer exists. Low ctDNA shedding in PDAC makes individual studies underpowered - exactly the scenario where a meta-analysis adds the most value.
Gap D - Temporal dynamics of ctDNA post-resection:
When to sample matters. Studies use pre-op, day-of-surgery, 1-month post-op, and surveillance time points inconsistently. No meta-analysis has modeled ctDNA timing (pre-op vs. immediately post-op vs. surveillance) as a moderator of recurrence prediction across GI cancers.
3. How to Sharpen the Topic
The phrase "ctDNA as a predictor of surgical margins AND recurrence" actually packages two slightly distinct questions. Here's how I'd position it:
Option A (Narrower, Higher Impact):
"Postoperative ctDNA for minimal residual disease detection and recurrence prediction after curative resection across GI cancers: a systematic review and meta-analysis"
- Covers all GI cancer subtypes
- Primary outcome: recurrence-free survival (RFS) stratified by ctDNA positivity
- Secondary: sensitivity/specificity for detecting actual margin involvement
- Novelty: pan-GI scope + structured analysis of sampling time points
- Feasibility: High - individual study data exists across all subtypes
Option B (More Novel, Harder to execute):
"Circulating tumor DNA as a predictor of pathological margin status (R0 vs. R1/R2) in resectable GI cancers: a systematic review"
- Directly targets the surgical margin gap
- Novelty: Highest - no prior systematic review exists
- Feasibility: Harder, because most primary studies don't report margin status as a dedicated ctDNA endpoint; you'd be extracting it from study subgroups
My recommendation: Combine both into a two-primary-outcome meta-analysis. Lead with ctDNA and recurrence (where poolable data exists), with margin status as a secondary/exploratory outcome. This gives you publishable primary results even if margin data is sparse, while simultaneously flagging the margin gap as a formal finding.
4. Methodological Considerations
- Heterogeneity will be high - different assay platforms (ddPCR, NGS-based tumor-informed, methylation-based), different cancer subtypes, different sampling time points. Plan subgroup analyses by cancer type and assay method upfront.
- Clonal hematopoiesis (CHIP) confounding - the 2026 Safiejko review flags this as a major uncontrolled variable in current studies; address it in your methods.
- KRAS mutation as a shared marker - KRAS mutations are present in ~40% of CRC, ~90% of PDAC, and ~10% of gastric cancers, which may allow cross-cancer pooling for a mutation-specific subgroup.
- Registration: Pre-register on PROSPERO before starting. A quick search suggests no registered protocol exists for this exact topic (another signal the gap is real).
5. Summary Assessment
| Criterion | Verdict |
|---|---|
| Is there a genuine literature gap? | Yes - especially for margin status and pan-GI pooling |
| Is there enough primary data to pool? | Yes for recurrence; limited but growing for margins |
| Has this specific meta-analysis been done? | No |
| Is the clinical question meaningful? | Yes - direct surgical and adjuvant decision-making implications |
| Publication potential? | High - Annals of Surgery, Gut, JAMA Oncology, Journal of Clinical Oncology are plausible targets |
This is a well-positioned, timely topic. The recurrence prediction arm gives you statistical power; the surgical margin arm gives you novelty. The main risk is heterogeneity in ctDNA assay methodology - budget for a thorough quality assessment (QUADAS-2 or GRADE) and you'll have a strong submission.
This is a shared conversation. Sign in to Orris to start your own chat.